Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of neoadjuvant DOX versus surgery plus postoperative XELOX in locally advanced gastric cancer
ChiCTR-IPR-14005415Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Oct 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel, oxaliplatin and capecitabine in gastric cancer (GC) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Radical resection rate. Started Oct 2014; status: recruiting.
02
Drugs
docetaxeloxaliplatincapecitabine
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR-IPR-14005415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-14005415.